Lupin receives USFDA tentative approval for Drospirenone Tablets

Global pharma major Lupin Limited (Lupin) has announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Drospirenone Tablets, 4 mg, to market a generic equivalent of Slynd Tablets, 4 mg, of Exeltis USA Inc.

Drospirenone Tablets (RLD Slynd) had estimated annual sales of USD 141 million in the U.S. (IQVIA MAT September 2022).

At around 1:31 PM, Lupin Ltd is currently trading at Rs709.65 per share down by Rs2.5 or 0.35% from its previous closing of Rs712.15 per share on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com